TGFB1 and neoplasm: Blocking TGF-β and its receptors was suggested to a therapeutic approach due to their ability to inhibit tumor growth [92, 93] and critical cell invasion [34, 94, 95], decrease tumourigenic potential [92, 96], and reduce metastatic dissemination [97] through various different pathways including the SMADs family [67, 98].